199 related articles for article (PubMed ID: 35707714)
1. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and
Yu Y; Wang Y; Zou Y; Yu Y
Dis Markers; 2022; 2022():5286820. PubMed ID: 35707714
[TBL] [Abstract][Full Text] [Related]
2. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer.
Oshi M; Tokumaru Y; Mukhopadhyay S; Yan L; Matsuyama R; Endo I; Takabe K
Cells; 2021 Mar; 10(3):. PubMed ID: 33804148
[TBL] [Abstract][Full Text] [Related]
3. Calpain 8 as a potential biomarker regulates the progression of pancreatic cancer via EMT and AKT/ERK pathway.
Song N; Cui K; Zeng L; Fan Y; Wang Z; Shi P; Su W; Wang H
J Proteomics; 2024 Jun; 301():105182. PubMed ID: 38697284
[TBL] [Abstract][Full Text] [Related]
4. EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway.
Xu J; Zhang W
Cancer Cell Int; 2021 Oct; 21(1):521. PubMed ID: 34627255
[TBL] [Abstract][Full Text] [Related]
5. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
[TBL] [Abstract][Full Text] [Related]
6. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
7. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
[TBL] [Abstract][Full Text] [Related]
8. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.
Zhuang H; Chen X; Wang Y; Huang S; Chen B; Zhang C; Hou B
Cancer Immunol Immunother; 2022 Mar; 71(3):601-612. PubMed ID: 34279685
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2.
Yang H; Li Z; Zhu S; Wang W; Zhang J; Zhao D; Zhang M; Zhu W; Xu W; Xu C
Front Immunol; 2024; 15():1347683. PubMed ID: 38343537
[TBL] [Abstract][Full Text] [Related]
11. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in Ovarian Cancer Patients: Evidence from Bioinformatics and In Vitro Level.
Song Y; Zhang J; Zhang L; Zhang S; Shen C
Comput Math Methods Med; 2022; 2022():7397250. PubMed ID: 36276992
[TBL] [Abstract][Full Text] [Related]
12. Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis.
Wang Y; Kong Y; Yang Q; Zhong C; Zhou D
Eur J Med Res; 2024 Apr; 29(1):221. PubMed ID: 38581008
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
14. High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients.
Yu LM; Zhu YS; Xu CZ; Zhou LL; Xue ZX; Cai ZZ
Clin Transl Oncol; 2019 Jul; 21(7):924-932. PubMed ID: 30565085
[TBL] [Abstract][Full Text] [Related]
15. LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients.
Zhang J; Zhang L; Li C; Yang C; Li L; Song S; Wu H; Liu F; Wang L; Gu J
Cell Oncol (Dordr); 2018 Feb; 41(1):73-84. PubMed ID: 29168159
[TBL] [Abstract][Full Text] [Related]
16. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
Chen Y; Wang C; Song J; Xu R; Ruze R; Zhao Y
Front Immunol; 2021; 12():758004. PubMed ID: 34887861
[TBL] [Abstract][Full Text] [Related]
17. High expression of ACKR1 predicts a good prognosis and suppresses sarcoma cell progression via regulating the tumor immune microenvironment.
Lin J; Liang F; Zheng L; Zeng J; Lin J
J Appl Genet; 2024 Feb; 65(1):121-136. PubMed ID: 38006471
[TBL] [Abstract][Full Text] [Related]
18. GJB3: a comprehensive biomarker in pan-cancer prognosis and immunotherapy prediction.
Zeng J; Li X; Zhang Y; Zhang B; Wang H; Bao S; Zu L; Zhang H; Cheng Y; Tang Q; Xu X; Xu S; Song Z
Aging (Albany NY); 2024 May; 16(9):7647-7667. PubMed ID: 38728250
[TBL] [Abstract][Full Text] [Related]
19. NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target.
Huang H; Hua Q
Int J Genomics; 2022; 2022():8348499. PubMed ID: 35535347
[TBL] [Abstract][Full Text] [Related]
20. Identification of Costimulatory Molecule-Related lncRNAs Associated With Gastric Carcinoma Progression: Evidence From Bioinformatics Analysis and Cell Experiments.
Yin Z; Qiao Y; Shi J; Bu L; Ao L; Tang W; Lu X
Front Genet; 2022; 13():950222. PubMed ID: 35991571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
